Ad
related to: ipf clinical trials 2023
Search results
Results from the WOW.Com Content Network
Admilparant is an investigational new drug being developed by Bristol-Myers Squibb for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). It is a first-in-class lysophosphatidic acid receptor 1 (LPA1) antagonist. [1] [2] As of 2024, admilparant is in Phase III clinical trials for both IPF and PPF. [2] [3]
Ziritaxestat is a small-molecule, selective autotaxin inhibitor that was investigated as a potential treatment for idiopathic pulmonary fibrosis (IPF). [1] Initially showing promise in early-phase studies, ziritaxestat underwent evaluation in two large-scale phase 3 clinical trials, ISABELA 1 and ISABELA 2.
Two replicate randomized clinical trials evaluated the efficacy and safety of nintedanib for the treatment of idiopathic pulmonary fibrosis. [34] The primary endpoint of the study was the effect on lung function, measured by forced vital capacity.
As of June 2011 the drug was being tested in humans (clinical trials) against IPF, renal disease, and cancer. [ 7 ] [ 8 ] On 13 August 2012, Genzyme applied to begin a Phase 2 clinical trial in primary focal segmental glomerulosclerosis [ 9 ] comparing fresolimumab versus placebo .
Idiopathic pulmonary fibrosis; Other names: Fibrosing alveolitis, cryptogenic fibrosing alveolitis, diffuse fibrosing alveolitis, usual interstitial pneumonitis, diffuse interstitial pneumonitis: Figure A shows the location of the lungs and airways in the body. The inset image shows a detailed view of the lung's airways and air sacs in cross ...
Clinical trials for Carlumab include studies of idiopathic pulmonary fibrosis, [8] [9] castration-resistant metastatic prostate cancer [1] [10] and solid tumors. [ 11 ] [ 12 ] Carlumab was being developed by Janssen Biotech prior to discontinuation in 2012 [ 13 ] due to limited success in clinical trials.
By July 2020, the drug completed Phase II clinical studies for cGvHD, IPF, and psoriasis. [11] Chronic graft-versus-host disease is a complication that can follow allogeneic stem cell or hematopoietic stem cell transplantation where the transplanted cells (graft) attack healthy cells (host). This causes inflammation and fibrosis in multiple ...
In October 2023, Reviva Pharmaceuticals released topline results from their pivotal RECOVER phase III clinical trial (NCT05184335). The RECOVER study was a 4-week, randomized, double-blind, placebo-controlled, multicenter trial where 411 patients received brilaroxazine 15 mg, 50 mg, or placebo once daily.
Ad
related to: ipf clinical trials 2023